Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAS Vaccine Candidate in Healthy Individuals
NCT04882514Phase 2Completed
- Sponsor
- University of Alberta
- Start
- Nov 2022
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of J8-K4S2, P*17-K4S2 in Group A streptococcal infection, sponsored by University of Alberta. Started Nov 2022; status: completed.
02
Drugs
J8-K4S2P*17-K4S2
03
Conditions
Group A streptococcal infection
Beyond the preview
Go deeper on NCT04882514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882514.